Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS)

Historical Holders from Q4 2014 to Q3 2025

Symbol
CHRS on Nasdaq
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
116,964,738
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
51,568,676
Holdings value
$84,529,366
% of all portfolios
0%
Number of holders
110
Number of buys
54
Number of sells
-47
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 6.6% -30% $7,617,701 -$3,458,214 7,617,701 -31.2% BlackRock, Inc. 31 Mar 2025
Bering Partners II, L.P. 6.5% $12,468,441 7,602,708 Evgeny Zaytsev ("Zaytsev") 05 Sep 2025
SATTERFIELD THOMAS A JR 5.2% $6,009,514 6,009,514 Thomas A. Satterfield, Jr. 14 Apr 2025
Rubric Capital Management LP 4.56% $5,258,754 5,258,754 Rubric Capital Management LP 31 Dec 2024

Institutional Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 51,568,676 $84,529,366 -$2,975,454 $1.64 110
2025 Q2 55,358,578 $40,439,575 -$4,928,963 $0.7313 109
2025 Q1 62,082,313 $50,064,190 -$6,457,989 $0.807 114
2024 Q4 65,594,814 $90,489,403 -$12,493,801 $1.38 121
2024 Q3 76,943,748 $79,924,458 -$11,982,900 $1.04 127
2024 Q2 82,580,425 $142,867,620 -$603,275 $1.73 132
2024 Q1 82,494,208 $197,162,680 -$5,908,937 $2.39 134
2023 Q4 81,477,441 $271,309,409 -$37,399,801 $3.33 153
2023 Q3 92,968,604 $347,619,918 +$14,526,156 $3.74 168
2023 Q2 86,685,207 $370,290,994 +$30,644,927 $4.27 159
2023 Q1 78,433,333 $536,456,842 -$2,030,485 $6.84 163
2022 Q4 78,672,183 $622,985,097 +$2,380,758 $7.92 160
2022 Q3 77,664,501 $746,258,214 -$14,908,210 $9.61 168
2022 Q2 78,904,235 $571,951,639 +$12,362,063 $7.24 171
2022 Q1 75,936,074 $979,679,788 -$19,093,537 $12.91 172
2021 Q4 76,732,060 $1,226,275,602 +$9,148,757 $15.96 190
2021 Q3 76,118,247 $1,224,124,361 -$23,896,897 $16.07 182
2021 Q2 77,861,825 $1,077,307,964 -$38,365,571 $13.83 184
2021 Q1 80,296,427 $1,174,206,082 -$126,382,516 $14.61 201
2020 Q4 86,846,381 $1,509,532,138 +$7,068,870 $17.38 191
2020 Q3 87,967,283 $1,615,322,964 -$17,575,985 $18.34 200
2020 Q2 86,666,598 $1,547,355,972 +$228,840,811 $17.86 187
2020 Q1 74,669,838 $1,211,513,949 +$27,802,781 $16.22 185
2019 Q4 72,711,303 $1,309,075,614 +$50,544,709 $18 184
2019 Q3 69,362,054 $1,405,299,052 +$54,882,205 $20.26 165
2019 Q2 66,788,293 $1,473,155,747 +$29,409,971 $22.1 145
2019 Q1 68,742,401 $937,662,508 +$43,941,561 $13.64 114
2018 Q4 65,705,169 $594,602,586 -$13,874,058 $9.05 107
2018 Q3 63,584,248 $1,049,141,419 +$28,536,991 $16.5 106
2018 Q2 61,953,349 $867,373,516 +$96,221,276 $14 112
2018 Q1 55,290,055 $610,960,009 +$32,866,184 $11.05 102
2017 Q4 49,467,518 $435,305,054 +$17,238,403 $8.8 92
2017 Q3 46,927,893 $626,702,945 +$87,202,617 $13.35 90
2017 Q2 40,123,971 $575,784,532 +$26,148,562 $14.35 105
2017 Q1 37,510,462 $793,275,948 +$210,973,219 $21.15 109
2016 Q4 29,921,898 $842,300,808 +$50,764,547 $28.15 122
2016 Q3 28,142,776 $753,581,042 +$78,368,033 $26.78 116
2016 Q2 25,321,897 $427,677,064 +$112,113,002 $16.89 86
2016 Q1 18,234,639 $387,025,000 +$29,114,088 $21.23 74
2015 Q4 16,721,851 $383,952,785 +$8,941,726 $22.96 76
2015 Q3 16,091,708 $322,474,715 +$17,279,435 $20.04 76
2015 Q2 15,045,116 $433,747,071 +$223,061,016 $28.9 73
2015 Q1 7,268,421 $221,671,439 -$28,139,852 $30.58 49
2014 Q4 9,850,113 $157,559,817 +$157,548,817 $16.32 37